These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 6872407)

  • 1. Effect of intravenous dose on hydralazine kinetics after administration.
    Ludden TM; Shepherd AM; McNay JL; Lin MS
    Clin Pharmacol Ther; 1983 Aug; 34(2):148-52. PubMed ID: 6872407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydralazine kinetics in hypertensive patients after intravenous administration.
    Ludden TM; Shepherd AM; McNay JL; Lin MS
    Clin Pharmacol Ther; 1980 Dec; 28(6):736-42. PubMed ID: 7438689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydralazine kinetics after single and repeated oral doses.
    Shepherd AM; Ludden TM; McNay JL; Lin MS
    Clin Pharmacol Ther; 1980 Dec; 28(6):804-11. PubMed ID: 7438695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, formulation, and clinical pharmacological evaluation of hydralazine pyruvic acid hydrazone in two healthy volunteers.
    Reece PA; Stafford I; Prager RH; Walker GJ; Zacest R
    J Pharm Sci; 1985 Feb; 74(2):193-6. PubMed ID: 3989691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotype.
    Shen DD; Hosler JP; Schroder RL; Azarnoff DL
    J Pharmacokinet Biopharm; 1980 Feb; 8(1):53-68. PubMed ID: 7381691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of hydralazine, apparent hydralazine and hydralazine pyruvic acid hydrazone in humans.
    Shepherd AM; Ludden TM; Haegele KD; Talseth T; McNay JL
    Res Commun Chem Pathol Pharmacol; 1979 Oct; 26(1):129-44. PubMed ID: 515498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma concentration and acetylator phenotype determine response to oral hydralazine.
    Shepherd AM; McNay JL; Ludden TM; Lin MS; Musgrave GE
    Hypertension; 1981; 3(5):580-5. PubMed ID: 7298112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acetylator phenotype and the antihypertensive response to hydralazine.
    Jounela AJ; Pasanen M; Mattila MJ
    Acta Med Scand; 1975 Apr; 197(4):303-6. PubMed ID: 1136859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype.
    Gonzalez-Fierro A; Vasquez-Bahena D; Taja-Chayeb L; Vidal S; Trejo-Becerril C; Pérez-Cardenas E; de la Cruz-Hernández E; Chávez-Blanco A; Gutiérrez O; Rodriguez D; Fernandez Z; Duenas-González A
    Int J Clin Pharmacol Ther; 2011 Aug; 49(8):519-24. PubMed ID: 21781652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of dose on acetylator phenotype distribution of hydralazine.
    Timbrell JA; Harland SJ; Facchini V
    Clin Pharmacol Ther; 1981 Mar; 29(3):337-43. PubMed ID: 7471604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?
    Ramsay LE; Silas JH; Ollerenshaw JD; Tucker GT; Phillips FC; Freestone S
    Eur J Clin Pharmacol; 1984; 26(1):39-42. PubMed ID: 6714290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variability of plasma hydralazine concentrations in male hypertensive patients.
    Ludden TM; McNay JL; Shepherd AM; Lin MS
    Arthritis Rheum; 1981 Aug; 24(8):987-93. PubMed ID: 7284051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of hydralazine elimination.
    Talseth T
    Clin Pharmacol Ther; 1977 Jun; 21(6):715-20. PubMed ID: 862310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypotensive effect of the hydralazine--acetone hydrazone in conscious rabbits: evidence for its back-conversion to hydralazine in vivo.
    Talseth T; McNay JL; Haegele KD
    J Cardiovasc Pharmacol; 1982; 4(3):370-4. PubMed ID: 6177931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and cardiovascular effects in rabbits of a major hydralazine metabolite, the hydralazine pyruvic-acid hydrazone.
    Talseth T; Haegele KD; McNay JL; Skrdlant HB; Clementi WA; Shepherd AM
    J Pharmacol Exp Ther; 1979 Dec; 211(3):509-13. PubMed ID: 512915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure.
    Garcés-Eisele SJ; Cedillo-Carvallo B; Reyes-Núñez V; Estrada-Marín L; Vázquez-Pérez R; Juárez-Calderón M; Guzmán-García MO; Dueñas-González A; Ruiz-Argüelles A
    J Clin Pharm Ther; 2014 Aug; 39(4):368-75. PubMed ID: 24702251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of response to intravenous hydralazine in hypertension.
    Shepherd A; Lin MS; McNay J; Ludden T; Musgrave G
    Clin Pharmacol Ther; 1981 Dec; 30(6):773-81. PubMed ID: 7307426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective high-performance liquid chromatographic assays for hydralazine and its metabolites in plasma of man.
    Reece PA; Cozamanis I; Zacest R
    J Chromatogr; 1980 Mar; 181(3-4):427-40. PubMed ID: 7391156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of hydralazine bioavailability by food.
    Melander A; Danielson K; Hanson A; Rudell B; Scherstén B; Thulin T; Wåhlin E
    Clin Pharmacol Ther; 1977 Jul; 22(1):104-7. PubMed ID: 872490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of hydralazine pyruvic acid hydrazone and its correlation with "apparent" hydralazine.
    Haegele KD; Talseth T; Skrdlant HB; Shepherd AM; Huff SL
    Arzneimittelforschung; 1981; 31(2):357-62. PubMed ID: 7194654
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.